PubMed · 2584592
Dosage cost analysis in glaucoma management.
Abstract
After the diagnosis of chronic open-angle glaucoma has been made, and the indications vs. contraindications of each of the potential first-line topical medications have been weighed, what medical therapy should be initiated if the most cost effective form of management is desired? We surveyed 40 pharmacies in four cities and found no statistical difference between the mean annual cost of therapy with timolol maleate (Timoptic), betaxolol (Betoptic), and pilocarpine. Statistically, both dipivefrin (Propine) and levobunolol (Betagan) were found to be more expensive. We also discovered that there are large variations in medication prices between various pharmacies. In order to enhance compliance, optometrists may want to know the pharmacies in their communities that offer antiglaucoma medications at reasonable prices.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
J B Gelvin, T M Goen. 1989. Dosage cost analysis in glaucoma management.. https://pubmed.ncbi.nlm.nih.gov/2584592/
Cite the original work for its findings. Save a collection to share your selection of sources.